New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Barnes, Edward L.; Burakoff, Robert

doi:10.1097/mib.0000000000000903

Cited by 30 publications

(32 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fecal and serologic biomarkers could also be used in the diagnosis and management of IBD . Several biomarkers specifically calprotectin, lactoferrin, anti‐glycoprotein 2, anti‐granulocyte macrophage colony‐stimulating factor, anti‐neutrophil cytoplasmic antibody, and anti‐ Saccharomyces cerevisiae antibody have been studied regarding the ability to identify patients with IBD precisely . However, they have limited diagnostic values for making definite diagnosis for IBD.…”

Section: Bacterial Infectious Agents Implicated In the Pathogenesis Omentioning

confidence: 99%

The role of bacteria in the inflammatory bowel disease development: a narrative review

Azimi

Nasiri

Chirani

et al. 2018

APMIS

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a general term used for the ulcerative colitis (UC) and Crohn's disease (CD); in addition, IBD principally refers to a chronic disease of the gastrointestinal tract in which mediated by immune system. Consequently, IBD could progress in individuals who are genetically prone. Infections role in the development of inflammatory disease of the gastrointestinal tract has been studied by quite many clinical studies; furthermore, the possible role of some pathogens in the development and exacerbation of the inflammatory disease of the gastrointestinal tract have been described. Evidently, the most indispensable pathogens that could be associated with the IBD disease, Mycobacterium avium subspecies paratuberculosis, Clostridium difficile, Escherichia coli, Listeria monocytogenes, Campylobacter concisus; as well as viruses, such as, cytomegalovirus, Epstein-Barr Virus, and measles virus are notable. A number of pathogenic parasites may also be involved in the development and progression of the disease. As a matter of fact, overexposure of immune system in the presence of excessive bacterial substances could also lead to the loss of immunological tolerance to the bacteria, which are commonly considered as the normal flora in the intestine; furthermore, it may subsequently elicit bowel inflammation and IBD development. In the current study, we discussed the most common bacterial pathogens that may be involved in the development of IBD; as well as, a comprehensive narrative review related to the evidences which support or ignore the possible role of bacteria in progression of IBD, indeed.

show abstract

Section: Bacterial Infectious Agents Implicated In the Pathogenesis Omentioning

confidence: 99%

The role of bacteria in the inflammatory bowel disease development: a narrative review

Azimi

Nasiri

Chirani

et al. 2018

APMIS

View full text Add to dashboard Cite

show abstract

“…High sensitivity CRP is a common non-specific marker of inflammation that can be elevated in patients with active IBD (20,21). However, CRP can be challenging to use as a biomarker due to its low specificity and high expression heterogeneity (22,23).…”

Section: Discussionmentioning

confidence: 99%

Peripheral blood miR‑372 as a biomarker for ulcerative colitis via direct targeting of NLRP12

Shen

2019

Exp Ther Med

View full text Add to dashboard Cite

The present study aimed to investigate the expression pattern and underlying mechanism of microRNA-372 (miR-372) in the progression of ulcerative colitis (UC). Reverse transcription-quantitative polymerase chain reaction was used to measure miR-372 expression levels in the blood and colonic mucosa tissue samples from patients with UC. The present study demonstrated that levels of miR-372 were significantly increased in the blood and colonic mucosa tissue samples from patients with UC compared with healthy controls. Furthermore, the level of serum miR-372 was positively correlated with the level of serum c-reactive protein. Receiver operating characteristic analysis indicated that levels of miR-372 detected in serum and tissue samples could be used to screen for patients with UC from healthy controls. These results indicated a potential role of miR-372 as a diagnostic marker and therapeutic target for patients with UC. Furthermore, a conserved miR-372 binding site in the 3'untranslated region of the NLR family pyrin domain containing 12 (NLRP12) was identified. Dual luciferase assay demonstrated that overexpression of miR-372 significantly reduced the relative luciferase activity of pmirGLO-NLRP12-3'UTR compared with control pmirGLO. In addition, western blot analysis indicated that overexpression of miR-372 significantly decreased the protein expression level of NLRP12. Therefore it was hypothesized that miR-372 may promote the progression of UC by suppressing NLRP12 protein expression and thereby inducing the excessive production of inflammatory cytokines. In conclusion, high levels of miR-372 detected in peripheral blood samples may serve a role as a potential biomarker to screen potential patients with UC from healthy controls.

show abstract

“…Basic research in IBD during the last few years has made significant advances in unveiling genetic loci of susceptibility, [ 10 , 11 ] revealing fundamental insights into enteric microbiota structures and their interaction with the innate and adaptive immune systems, [ 12 ] as well as discovering novel functions for and the regulation of previously recognized innate immune cells [ 13 ]. Additional research efforts have been initiated to predict treatment outcome, [ 14 , 15 ] and define risk stratification for disease progression in addition to shedding light on potential environmental triggers and their role in initiating post-infectious functional gastrointestinal disorders such as irritable bowel syndrome and IBD [ [16] , [17] , [18] , [19] , [20] ].…”

Section: Study Rationalementioning

confidence: 99%

Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics

Porter

Riddle

Gutiérrez

et al. 2019

Contemporary Clinical Trials Communications

View full text Add to dashboard Cite

Purpose The etiology of Inflammatory Bowel Disease (IBD) remains currently unknown but evidence would suggest that it results from a complex interplay between genetic susceptibility genes, the intestinal microbiome and the environment, resulting in an increased response towards microbial and self-antigens, followed by the development of pre-clinical intestinal inflammation as a precursor to overt clinical disease. Efforts are needed to provide insights into the characterization of the disease, the possible prediction of complications, and the detection of a pre-clinical disease state where, through early screening and intervention, disease course can be reversed, attenuated or even prevented. A consortium of academic, industry and governmental organization investigators initiated this study to enable an assessment of pre-disease biomarkers in patients newly diagnosed with Crohn's disease (CD) and ulcerative colitis (UC). Participants A retrospective cohort of 1000 UC and 1000 CD cases with 500 matched controls was drawn from an active duty US military personnel population with relevant inclusion criteria with three associated pre-disease and a single disease-associated archived serum samples. Findings to date The PREDICTS study has been established as a biorepository platform study to perform novel discovery and analysis efforts in the field of IBD and proteomic systems biology. Future plans This study is poised to enable the assessment of novel biomarkers within the serum compartment to be analyzed with the goal of identifying pre-disease signals that ultimately predict disease risk, and further elucidate disease pathogenesis in the early stages of the disease process, and identify novel exposures that increase disease risk.

show abstract

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Cited by 30 publications

References 142 publications

The role of bacteria in the inflammatory bowel disease development: a narrative review

The role of bacteria in the inflammatory bowel disease development: a narrative review

Peripheral blood miR‑372 as a biomarker for ulcerative colitis via direct targeting of NLRP12

Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics

Contact Info

Product

Resources

About